Day: May 11, 2023

Conference Call on Thursday, May 11, 2023, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, May 11, 2023 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter ended March 31, 2023 (“First Quarter 2023”). First Quarter 2023 HighlightsDuring First Quarter 2023, student enrollment was 1,097, an increase of 10.0% from 997 in the prior-year period. Excluding the 171 enrollments from the foreign language training business ACG disposed of in Third Quarter 2022, student enrollment increased by 271 compared to the prior-year period. Of the 1,097 students, 648 were enrolled in ACG’s...

SHAKOPEE, Minn., May 11, 2023 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today reported financial results for the first quarter ended March 31, 2023.($ in thousands, except per share data and percentages)  Three Months Ended March 31,   2023    2022   ChangeNet revenues $13,300   $13,638   -2.5%           Net income   $2,771   $1,774   56.2%           Adjusted EBITDA (1) $2,482   $3,547   -30.0%           Basic EPS $0.57   $0.37   53.8%Diluted EPS $0.56   $0.36   54.2%(1) Adjusted EBITDA, a non-GAAP measure, excludes certain items from net income, a GAAP measure. Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results. Definitions, disclosures, and reconciliations...

First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestonesSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate...

– On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 – – First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing with AAVHSCs, at Upcoming ASGCT Meeting – – Solid Financial Position with Anticipated Cash Runway into Fourth Quarter 2024 – BEDFORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments. “We look forward to announcing the first gene editing data in people with PKU, as we are on track to report initial clinical data mid-year 2023 from our pheEDIT trial evaluating HMI-103,” said Albert Seymour, Ph.D., President...

PORTLAND, Maine, May 11, 2023 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023. Management’s Discussion:“Our unaudited, preliminary product sales were first reported on April 5, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell. “We have no changes to those figures.” “We have just persevered through the most difficult quarter in the history of the Company,” continued Mr. Brigham. “As previously disclosed, we made the strategic decision to significantly reduce production output to remediate a production contamination...

Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug conjugate (ADC), for treatment of CD123+ hematologic malignancies on track for mid-2023 Cash balance expected to support planned operations into late 2024 PALO ALTO, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The ADC space is going through an exciting period of innovation,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “The therapeutic...

Fourth Generation Ankaa-1 Chip Demonstrates Median 2-Qubit Gate Fidelity and Gate Speed Improvements Superior to Aspen M-3 BERKELEY, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial HighlightsTotal revenues for the three months ended March 31, 2023 were $2.2 million, compared to $2.1 million in the same period of 2022. Total operating expenses for the three months ended March 31, 2023 were $23.7 million, compared to $27.0 million in the same period of 2022. Operating loss for the three months ended March 31, 2023 was $22.0 million, compared to $25.3 million in the same period of 2022. Net loss for the three...